Merck & Co., Inc. (LON: MRK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
53.17
+0.17 (0.31%)
Dec 23, 2024, 9:37 AM BST
-40.93%
Market Cap 197.28B
Revenue (ttm) 47.13B
Net Income (ttm) 9.06B
Shares Out n/a
EPS (ttm) 3.57
PE Ratio 21.77
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,238
Open 54.00
Previous Close 53.00
Day's Range 53.17 - 54.00
52-Week Range 48.00 - 93.50
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 4, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]

Founded 1891
Employees 72,000
Stock Exchange London Stock Exchange
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial numbers in USD Financial Statements

News

Mike Ashley’s Frasers buys £3m stake in Marks Electrical

In a stock market filing, Marks revealed that Frasers has bought 6.73 million shares in the business.

27 days ago - Evening Standard

Three Quick Facts: AstraZeneca, Marks Electrical, BAE Systems

Buoyant demand sustains revenue growth at AstraZeneca, solid revenue growth at Marks Electrical, BAE Systems on track following upgrades

5 weeks ago - The Armchair Trader